Retinopathy progression in type 2 diabetes [8]

New England Journal of Medicine

Volumn 363, Issue 22, 2010, Pages 2172-2173

  Rind, David M ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIABETIC RETINOPATHY; DISEASE SEVERITY; EARLY TREATMENT DIABETIC RETINOPATHY STUDY SEVERITY SCALE; HUMAN; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RATING SCALE; VISUAL IMPAIRMENT; BLOOD; DISEASE COURSE; DRUG COMBINATION; DYSLIPIDEMIA; NOTE; TREATMENT OUTCOME;

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL;

CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FENOFIBRATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; TRIGLYCERIDES; TREATMENT OUTCOME;

EID: 78649401210     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1009236     Document Type: Letter

References (18)

1. The ACCORD Study Group and ACCORD Eye Study Group Effects of medical therapies on retinopathy progression in type 2 diabetes N Engl J Med 363 2010 233 244
2. The Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2545 2559
3. The ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574 [Erratum, N Engl J Med 2010;362:1748.]
4. T Ohno O Kinoshita H Fujita Detecting occult coronary artery disease followed by early coronary artery bypass surgery in patients with diabetic retinopathy: report from a diabetic retinocoronary clinic J Thorac Cardiovasc Surg 139 2010 92 97
5. M Meissner M Stein C Urbich PPARalpha activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation Circ Res 94 2004 324 332
6. D Panigrahy A Kaipainen S Huang PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition Proc Natl Acad Sci U S A 105 2008 985 990
7. The Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2545 2559
8. A Keech RJ Simes P Barter Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861 [Erratum, Lancet 2006;368:1415, 1420.]
9. TY Wong G Liew P Mitchell Clinical update: new treatments for age-related macular degeneration Lancet 370 2007 204 206
10. AC Keech P Mitchell PA Summanen Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial Lancet 370 2007 1687 1697
11. MF Perutz C Poyart Bezafibrate lowers oxygen affinity of haemoglobin Lancet 2 1983 881 882
12. RF Gariano TW Gardner Retinal angiogenesis in development and disease Nature 438 2005 960 966
13. C Poyart MC Marden J Kister Bezafibrate derivatives as potent effectors of hemoglobin Methods Enzymol 232 1994 496 513
14. DM Nathan PA Cleary JY Backlund Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N Engl J Med 353 2005 2643 2653
15. RR Holman SK Paul MA Bethel DR Matthews HA Neil 10-Year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 2008 1577 1589
16. United Kingdom Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes BMJ 317 1998 703 713 [Erratum, BMJ 1999;318:29.]
17. The ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574 [Erratum, N Engl J Med 2010;362:1748.]
18. Early Treatment Diabetic Retinopathy Study Research Group Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS report number 12 Ophthalmology 98 Suppl 1991 823 833